Morgan Stanley raised the firm’s price target on PTC Therapeutics (PTCT) to $92 from $90 and keeps an Overweight rating on the shares. The firm updated its model for actuals and management commentary following PTC’s Q4 results call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $120 from $119 at Barclays
- PTC Therapeutics price target raised to $82 from $78 at RBC Capital
- PTC Therapeutics price target lowered to $93 from $97 at BofA
- Sephience-Led Growth, Global Expansion, and Robust Pipeline Underpin Buy Rating on PTC Therapeutics
- PTC Therapeutics price target lowered to $86 from $93 at Wells Fargo